The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model

Chronobiology International

Volumn 32, Issue 5, 2015, Pages 608-614

  Sallam, Hatem ^a   El Serafi, Ahmed T ^a,b,c   Filipski, Elisabeth ^d,e   Terelius, Ylva ^f   Lévi, Francis ^d,e   Hassan, Moustapha ^a,g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SHARJAH   (United Arab Emirates)

^c Suez Canal University Faculty of Medicine   (Egypt)

^d INSERM   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f MEDIVIR AB   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biodistribution; Chronopharmacology; Metabolism; Pharmacokinetics; Roscovitine

Indexed keywords

MUS;

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; ROSCOVITINE;

ANIMAL; ANIMAL MODEL; ANTAGONISTS AND INHIBITORS; CHRONOPHARMACOKINETICS; CIRCADIAN RHYTHM; MALE; METABOLISM; MOUSE; NEOPLASMS; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHRONOPHARMACOKINETICS; CIRCADIAN RHYTHM; CYCLIN-DEPENDENT KINASES; MALE; MICE; MODELS, ANIMAL; NEOPLASMS; PROTEIN KINASE INHIBITORS; PURINES;

EID: 84931825306     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2015.1022782     Document Type: Article

References (49)

1. Afsharian P, Terelius Y, Hassan Z, et al. (2007). The effect of repeated administration of cyclophosphamide on cytochrome P450 2B in rats. Clin Cancer Res. 13: 4218-24
2. Aldoss IT, Tashi T, Ganti AK. (2009). Seliciclib in malignancies. Expert Opin Investig Drugs. 18: 1957-65
3. Altinok A, Levi F, Goldbeter A. (2009). Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci. 36: 20-38
4. Baraldo M. (2008). The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol. 4: 175-92
5. Bellet MM, Sassone-Corsi P. (2010). Mammalian circadian clock and metabolism-The epigenetic link. J Cell Sci. 123: 3837-48
6. Benson C, White J, De Bono J, et al. (2007). A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer. 96: 29-37
7. Bettayeb K, Baunbaek D, Delehouze C, et al. (2010). CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer. 1: 369-80
8. Bettayeb K, Sallam H, Ferandin Y, et al. (2008). N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Mol Cancer Ther. 7: 2713-24
9. Bukanov NO, Moreno SE, Natoli TA, et al. (2012). CDK inhibitors Rroscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle. 11: 4040-6
10. Dallmann R, Brown SA, Gachon F. (2014). Chronopharmacology: New insights and therapeutic implications. Annu Rev Pharmacol Toxicol. 54: 339-61
11. Daujat M, Clair P, Astier C, et al. (1991). Induction, regulation and messenger half-life of cytochromes P450 IA1, IA2 and IIIA6 in primary cultures of rabbit hepatocytes. CYP 1A1, 1A2 and 3A6 chromosome location in the rabbit and evidence that posttranscriptional control of gene IA2 does not involve mRNA stabilization. Eur J Biochem. 200: 501-10
12. Delehouze C, Godl K, Loaec N, et al. (2013). CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene. 33: 5675-87
13. Doi M, Hirayama J, Sassone-Corsi P. (2006). Circadian regulator CLOCK is a histone acetyltransferase. Cell. 125: 497-508
14. Eckel-Mahan K, Sassone-Corsi P. (2013). Epigenetic regulation of the molecular clockwork. Prog Mol Biol Transl Sci. 119: 29-50
15. Eckel-Mahan K, Sassone-Corsi P. (2013). Metabolism and the circadian clock converge. Physiol Rev. 93: 107-35
16. El-Serafi I, Terelius Y, Twelkmeyer B, et al. (2013). Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 913-914: 98-105
17. Filipski E, Delaunay F, King VM, et al. (2004). Effects of chronic jet lag on tumor progression in mice. Cancer Res. 64: 7879-85
18. Filipski E, King VM, Li X, et al. (2003). Disruption of circadian coordination accelerates malignant growth in mice. Pathol Biol (Paris). 51: 216-19
19. Filipski E, Lemaigre G, Liu XH, et al. (2004). Circadian rhythm of irinotecan tolerability in mice. Chronobiol Int. 21: 613-30
20. Filipski E, Li XM, Levi F. (2006). Disruption of circadian coordination and malignant growth. Cancer Causes Control. 17: 509-14
21. Gachon F, Olela FF, Schaad O, et al. (2006). The circadian PARdomain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 4: 25-36
22. Gholam D, Giacchetti S, Brezault-Bonnet C, et al. (2006). Chronomodulated irinotecan, oxaliplatin, and leucovorinmodulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan-And oxaliplatin-resistant metastatic colorectal cancer. Oncologist. 11: 1072-80
23. Innominato PF, Focan C, Gorlia T, et al. (2009). Circadian rhythm in rest and activity: A biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 69: 4700-7
24. Iurisci I, Filipski E, Reinhardt J, et al. (2006). Improved tumor control through circadian clock induction by Seliciclib, a cyclindependent kinase inhibitor. Cancer Res. 66: 10720-8
25. Iurisci I, Filipski E, Sallam H, et al. (2009). Liver circadian clock, apharmacologic target of cyclin-dependent kinase inhibitor seliciclib. Chronobiol Int. 26: e1169-88
26. Janich P, Toufighi K, Solanas G, et al. (2013). Human epidermal stem cell function is regulated by circadian oscillations. Cell Stem Cell. 13: 745-53
27. Knockaert M, Greengard P, Meijer L. (2002). Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 23: 417-25
28. Lambert LA, Qiao N, Hunt KK, et al. (2008). Autophagy: A novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res. 68: 7966-74
29. Le Tourneau C, Faivre S, Laurence V, et al. (2010). Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclindependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer. 46: 3243-50
30. Levi F, Okyar A, Dulong S, et al. (2010). Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 50: 377-421
31. Levi F, Schibler U. (2007). Circadian rhythms: Mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 47: 593-628
32. Levi FA. (2008). The circadian timing system: A coordinator of life processes: Chronobiological investigations. Implications for the rhythmic delivery of cancer therapeutics. IEEE Eng Med Biol Mag. 27: 17-19
33. Lin JH, Lu AY. (1997). Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 49: 403-49
34. Lofgren S, Baldwin RM, Hiratsuka M, et al. (2008). Generation of mice transgenic for human CYP2C18 and CYP2C19: Characterization of the sexually dimorphic gene and enzyme expression. Drug Metab Dispos. 36: 955-62
35. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem. 193: 265-75
36. McClue SJ, Stuart I. (2008). Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 36: 561-70
37. Meijer L, Raymond E. (2003). Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res. 36: 417-25
38. Mormont MC, Levi F. (2003). Cancer chronotherapy: Principles, applications, and perspectives. Cancer. 97: 155-69
39. Ohdo S. (2007). Chronopharmacology focused on biological clock. Drug Metab Pharmacokinet. 22: 3-14
40. Ohdo S, Koyanagi S, Matsunaga N. (2010). Chronopharmacological strategies: Intra-And inter-individual variability of molecular clock. Adv Drug Deliv Rev. 62: 885-97
41. Phelps MA, Lin TS, Johnson AJ, et al. (2009). Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 113: 2637-45
42. Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol Int. 27: 1911-29
43. Raje N, Kumar S, Hideshima T, et al. (2005). Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 106: 1042-7
44. Relogio A, Thomas P, Medina-Perez P, et al. (2014). Ras-mediated deregulation of the circadian clock in cancer. PLoS Genet. 10: e1004338
45. Sallam H, El-Serafi I, Meijer L, Hassan M. (2013). Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor-CR8-in mice. BMC Pharmacol Toxicol. 14: 50
46. Sallam H, Jimenez P, Song H, et al. (2008). Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain. Pharmacol Res. 58: 32-7
47. Vita M, Abdel-Rehim M, Nilsson C, et al. (2005). Stability, pKa and plasma protein binding of roscovitine. J Chromatogr B Analyt Technol Biomed Life Sci. 821: 75-80
48. Vita M, Meurling L, Pettersson T, et al. (2004). Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: Pharmacokinetics of roscovitine in rat. J Pharm Biomed Anal. 34: 425-31
49. Zhang Z, Liu Q, Leskov KS, et al. (2013). Roscovitine suppresses CD4 + T cells and T cell-mediated experimental uveitis. PLoS One. 8: e81154